DOI: https://doi.org/10.36347/sjams.2025.v13i07.025

Pages: 1512-1517

Background: Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents has become increasingly important in managing vitreoretinal diseases such as age-related macular degeneration, central or branch retinal vein occlusion, and diabetic maculopathy, which are rising globally. This study aimed to assess the effect of intravitreal Bevacizumab injection on intraocular pressure (IOP) and mean ocular perfusion pressure (MOPP). Methods: This prospective observational study was conducted in the Department of Ophthalmology, BSMMU, Dhaka from March 2018 to August 2020. Within the period, total 85 cases of different vitreoretinal diseases those meet the inclusion criteria were included in study after receiving informed consent from the patient. Results: Mean IOP was 13.39±3.92 mmHg before injection, 16.65±4.48 mmHg at 30 minutes, 13.40±3.50 mmHg at 1 day, and 13.12±3.27 mmHg at 7 days. Mean MOPP was 50.94±6.87 mmHg before injection, 48.12±7.15 mmHg at 30 minutes, 50.47±6.64 mmHg at 1 day, and 50.66±4.98 mmHg at 7 days. A significant change was observed in IOP and MOPP within 30 minutes post-injection (p < 0.05), but not at 1 or 7 days (p > 0.05). Conclusion: After analyzing the results of present study it can be concluded that IOP is significantly increased within 30 minutes after injection and recover to their pre-injection value within 1 day after injection, this observation continued on 7th day follow up also. And MOPP is significantly decreased within 30 minutes after injection and recover to their pre-injection value within 1 days after injection and this observation continued on 7th day follow up also.